Janus kinase (JAK) inhibitors are a group of medications that can treat various types of arthritis, including rheumatoid arthritis (RA), cancer, dermatological conditions like atopic dermatitis and ...

One class of ARTs, integrase inhibitors, has become a standard HIV treatment. Research shows they work well to keep the disease in check. Here’s what you need to know. Integrase inhibitors are ...

Also known as selective COX-2 inhibitors, these medications treat inflammatory pain. Selective COX-2 inhibitors are a type of nonsteroidal anti-inflammatory medication (also known as NSAIDs).

Having had some inquiries made of us respecting the amount of corrosion which iron undergoes in water, we present the following remarks of Mr, Adie, of Liverpool, Eng,, which were read sometime ...

The inhibitors bind to the catalytic zinc ion within the enzyme cavity. Several such derivatives are clinically used inhibitors, such as acetazolamide, methazolamide, ethoxzolamide ...

Sanofi’s BTK in­hibitor rilz­abru­ti­nib helped 23% of adults with a rare au­toim­mune blood dis­or­der achieve tar­get platelet counts in a Phase 3 tri­al, com­pared to … ...

The term “protease inhibitor” refers to a class of medications rather than to a single medication. Specifically, they are antiviral drugs. But unlike the many, more common antiviral drugs that ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to launch its JAK inhibitor competitor to Eli Lilly and Incyte’s Olumiant and ...

Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China ...

Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings Rilzabrutinib is an oral inhibitor of Bruton’s tyrosine kinase (BTK), a protein that ...

Revumenib is the first drug in a new class called menin inhibitors to receive FDA approval. The trial that brought about the drug’s approval was led by Eytan Stein, MD, Chief of the Leukemia Service ...